Please login to the form below

Not currently logged in
Email:
Password:

non-small cell lung cancer

This page shows the latest non-small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

least in certain settings such as first-line non-small cell lung cancer. ... It seems that this principle does not extend across all cancer types, with this stumble in melanoma a clear example of that.

Latest news

  • Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

    TAK-788 for non-small cell lung cancer:Phase 1/2 results with EGFR/HER2 inhibitor TAK-788 in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations – ... a blood disorder that results in blood clots forming in small blood vessels

  • BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

    BMS has previously evaluated Opdivo as a monotherapy treatment in front-line lung cancer, although its efforts in this area were fruitless. ... BMS is also looking to edge into the lung cancer market, with a recent phase 3 trial demonstrating positive

  • BMS’ Opdivo stalls in Q3, but overall figures still top expectations BMS’ Opdivo stalls in Q3, but overall figures still top expectations

    The company’s chief executive Giovanni Caforio (pictured below, left) talked up new trial results for the drug alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) in first-line non-small cell lung ... first-line lung cancer market,” said Caforio

  • Merck CFO: we’re not only about Keytruda Merck CFO: we’re not only about Keytruda

    Keytruda is approved for a long list of cancer types, but its sales growth has been driven largely by its dominance of the non-small cell lung cancer (NSCLC) market, and ... Merck also pointed to the potential for Keytruda growth in new indications like

  • AZ’s Imfinzi combo scores in front-line lung cancer AZ’s Imfinzi combo scores in front-line lung cancer

    Attempts to catch up to BMS and Merck in non-small cell lung cancer. ... It did not result in increased discontinuation of therapy. “The POSEIDON trial provides evidence of the efficacy of Imfinzi in patients with Stage IV non-small cell lung cancer.

More from news
Approximately 1 fully matching, plus 586 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... For patients with previously chemo-treated advanced non-small cell lung cancer, Opdivo reduced the risk of death in

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... Its Imfinzi has secured the first-ever US and EU approval in

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Spotlight interview: 15 minutes on insights and market research in pharma
Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma...
WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....

Infographics